Could a Telomere-Targeting drug revive immunotherapy in lung cancer?
Disease control
Ongoing
This phase 2 trial tests a new drug called THIO, which targets telomeres in cancer cells, followed by the immunotherapy cemiplimab (LIBTAYO) in people with advanced non-small cell lung cancer. The study includes about 227 participants whose cancer has progressed after initial tre…
Phase: PHASE2 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC